Evidence map›Paper›PMID 24840058›Full record

ReviewCurrent opinion in HIV and AIDS2014

Identifying the appropriate comparison group for HIV-infected individuals.

Cherise Wong, Keri Althoff, Stephen J Gange

Abstract readReview
In one paragraph

Review in Current opinion in HIV and AIDS, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
  8. Cancer Risk in Older Persons Living With Human Immunodeficiency Virus Infection in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
  9. Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
  10. Article
  11. Aging and HIV: an evolving understanding.Current opinion in HIV and AIDS · 2014
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Cherise WongJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Keri Althoff
Stephen J Gange

Funding

North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
EPIDEMIOLOGY AND BIOSTATISTICS OF AGINGT32AG000247 · NIA · JOHNS HOPKINS UNIVERSITY · PI Karen J. Bandeen-Roche · 1996 to 2026
$13.2M
Challenging and Expanding Paradigms of Aging with HIVK01AI093197 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ALTHOFF, KERI NICOLE · 2011 to 2015
$646k
Multimorbidity among HIV-Infected Adults in North America from 2000-2010F31DA037788 · NIDA · JOHNS HOPKINS UNIVERSITY · PI WONG, CHERISE · 2014 to 2015
$86k
NIAID NIH HHS K01 AI093197NIAID NIH HHS K01-AI093197NIAID NIH HHS U01 AI042590NIAID NIH HHS U01 AI069918NIAID NIH HHS U01-AI069918NIAID NIH HHS U01-AI42590NIA NIH HHS T32 AG000247NIA NIH HHS T32-AG000247NIDA NIH HHS F31 DA037788NIDA NIH HHS F31-DA037788NIDA NIH HHS U01 DA036935
6 · The paper itself

Abstract

purpose of reviewHIV-infected individuals are living longer as a result of effective treatment. Age-related comorbidities now account for the majority of morbidity and mortality among treated HIV-infected adults. Previous findings regarding the age at, and risk of, these comorbidities have been mixed, sparking debate in the field. Discerning potential differences in the occurrence and burden of age-related comorbidities among treated HIV-infected adults as compared with uninfected adults of the same age requires careful selection of the appropriate uninfected comparison group. RECENT

findingsThe validity of comparisons with HIV-uninfected populations is threatened when differences in demographic, clinical, and lifestyle characteristics between HIV-infected and uninfected adults are not considered. Identifying a pool of HIV-uninfected individuals from existing secondary data resources and employing selection methodologies may be a novel approach to reduce threats to internal validity. Issues related to identifying data sources, understanding inclusion criteria, determining measurement error, and threats to inference are discussed. SUMMARY: The development of clinical interventions targeting age-related comorbidities will rely on deriving valid inferences from appropriate comparison groups. The use of secondary data resources and selection methodology to create the appropriate uninfected comparison group is an attractive approach in the setting of finite resources, but are not without limitations.

Indexed as

AgingComorbidityControl GroupsBiomedical ResearchHIV InfectionsHumans

Identifiers

PMID24840058
PMCPMC4105851

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.